Open AccessAngiotensin Receptor-Neprilysin Inhibition Improves Blood Pressure and Heart Failure Control in Left Ventricular Assist Device Patients
Author(s) -
Rachel Goldberg,
Kristin Freed,
Nancy Klemans,
Rebecca Fioretti,
Chun Woo Choi,
Ahmet Kilic,
Luigi Adamo,
Roberta Florido,
Kavita Sharma,
Nisha A. Gilotra,
Steven Hsu
Publication year - 2021
Publication title -
asaio journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.961
H-Index - 66
eISSN - 1538-943X
pISSN - 1058-2916
DOI - 10.1097/mat.0000000000001435
Subject(s) - neprilysin , heart failure , cardiology , ejection fraction , medicine , sacubitril , valsartan , angiotensin receptor , blood pressure , renin–angiotensin system , angiotensin ii , chemistry , biochemistry , enzyme
Angiotensin receptor-neprilysin inhibitors (ARNIs) greatly benefit functional capacity and longevity in heart failure with reduced ejection fraction (HFrEF). Angiotensin receptor-neprilysin inhibitors remain underutilized and unstudied, however, in left ventricular assist device (LVAD) recipients, in spite of their underlying HFrEF. In this case series, we studied the feasibility and short-term efficacy of ARNI utilization in 21 LVAD patients. Angiotensin receptor-neprilysin inhibitor initiation was successful in most, resulting in significant consolidation of blood pressure (BP) medical management and marked improvements in both functional capacity and diuretic requirements. Angiotensin receptor-neprilysin inhibitors are safe, feasible, and within a short timeframe benefit BP and heart failure control in LVAD recipients.